Severe hemolytic anemia due to cold agglutinin complicating untreated chronic hepatitis C: efficacy and safety of anti-CD20 (rituximab) treatment.
Autoimmune hemolytic anemia (AIHA) is rare and difficult to treat during chronic hepatitis C. We report herein the case of a hepatitis C patient with severe and resistant AIHA who experienced a good and sustained response with anti-CD20 monoclonal antibody treatment.
Etienne
Anne
A
Service de Médecine Interne, Hôpital de la Conception, Marseille, France.
Gayet
Stéphane
S
Vidal
Florian
F
Poullin
Pascale
P
Brunet
Corinne
C
Harlé
Jean-Robert
JR
Kaplanski
Gilles
G
D000368:Aged; D000744:Anemia, Hemolytic, Autoimmune / Q000097:blood / Q000188:drug therapy* / Q000209:etiology* / Q000473:pathology; D018951:Antigens, CD20 / Q000009:adverse effects / Q000627:therapeutic use*; D019698:Hepatitis C, Chronic / Q000097:blood / Q000150:complications*; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D018951:Antigens, CD20